ArticleJournal of surgical oncology2026
Safety of Pre-Operative Radiotherapy Combined With Intraoperative Radiotherapy for Retroperitoneal Sarcoma.
Article in Journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Safety of Pre-Operative Radiotherapy Combined With Intraoperative Radiotherapy for Retroperitoneal Sarcoma.Journal of surgical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundLocal recurrence in retroperitoneal sarcomas (RPS) with high-risk surgical margins remains a significant clinical challenge. Previous randomized trials have evaluated neoadjuvant external beam radiation therapy (EBRT) without intraoperative radiotherapy (IORT). Following multidisciplinary consensus, our institution employs neoadjuvant EBRT combined with IORT for the management of RPS. This study evaluates the safety and feasibility of this combined strategy.
methodsA single-institution retrospective review was conducted of patients with RPS treated with neoadjuvant EBRT, surgical resection, and IORT between June 1, 2004, and June 30th, 2024. Postoperative complications and 90-day readmission rates were identified through electronic medical records, pathology reports, and death registries. Postoperative complications were graded by the Clavien-Dindo (CD) classification system.
resultsTwenty-eight patients underwent neoadjuvant EBRT followed by resection with IORT. The median age was 66 years (IQR 59.6-69.6 years) and 57% were female. Twenty-three patients (83%) were treated for primary disease, and five patients (17%) were being treated for recurrent disease, with one patient undergoing treatment for recurrence twice. Median number of neoadjuvant EBRT cycles was 25 (IQR 25). Patients received a median neoadjuvant EBRT dose of 4,500 cGy (IQR 45-4,500 cGy) and median IORT dose of 1375 cGy (IQR 1250-1500 cGy). The median tumor size was 11.9 cm (IQR 7-22.6 cm) and most commonly leiomyosarcoma (42%) and well-differentiated liposarcoma (29%). Multi-visceral resection was required in 71% of cases, most often involving the kidney (64%), adrenal gland (39%), and gallbladder (32%). Complete (R0) resection was achieved in 14 (54%) patients, while incomplete (R1) resection was achieved in 12 (46%) patients. Median hospital stay was 7 days (IQR 6-9 days). Postoperative morbidity occurred in 78% of patients, with 25% experiencing major (Clavien-Dindo III-V) complications. There was one mortality within 90 days of index operation.
conclusionNeoadjuvant EBRT followed by resection with IORT is associated with frequent low-grade complications and a 25% rate of major complications, similar to neoadjuvant EBRT alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.